CellaVision quantifies the outlook for the first quarter of 2017. Sales exceeding SEK 93 million in the first quarter of 2017
(Thomson Reuters ONE) -
The information was released for public disclosure on April 7, 2017 at 08.20
CET.
CellaVision AB (publ) announces preliminary figures due to the company's
significantly increased sales in the first quarter of 2017 compared to the same
period last year. The company announces preliminary net sales exceeding SEK 93
million (58.3) with a revenue growth of at least 60 percent and an operating
profit in excess of SEK 34 million (13.9).
CellaVision has an uneven order flow and revenue over the year, and the
variation in order volumes in individual quarters may be significant. The
variations between different geographical regions may also be substantial.
During the first quarter of 2017, CellaVision had exceptional sales in the
Americas and APAC and a more stable development in EMEA compared to the same
period last year. The strong regional sales development is the main reason for
the increase in sales for the first quarter of 2017.
The company will publish its interim report for the first quarter of 2017 on May
4, 2017.
For more information please contact:
Zlatko Rihter, President and Chief Executive Officer, CellaVision AB
Phone: +46 (0) 733- 62 11 06 | E-mail: zlatko.rihter(at)cellavision.com
About CellaVision
CellaVision is an innovative, global medical technology company that develops
and sells its own leading systems for routine analysis of blood and other body
fluids in health care services. The products replaces manual laboratory work,
and secure and support effective workflows and skills development within and
between hospitals. The company has leading-edge expertise in image analysis,
artificial intelligence and automated microscopy. Sales are via global partners
with support from the parent company in Lund and by the market support
organizations in the US, Canada, China, Sweden, Japan, Dubai, Korea, Australia
and France. In 2016 sales were SEK 265 million and the company's growth target
is 15 % per year over an economic cycle. CellaVision's registered office is in
Lund, Sweden. The share is listed on the Nasdaq Stockholm, Small Cap list. Read
more at www.cellavision.com
Pdf:
http://hugin.info/132164/R/2094454/792048.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellaVision AB via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 07.04.2017 - 08:20 Uhr
Sprache: Deutsch
News-ID 535150
Anzahl Zeichen: 2823
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 154 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CellaVision quantifies the outlook for the first quarter of 2017. Sales exceeding SEK 93 million in the first quarter of 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
